Skip to content

Methylprednisolone for primary supratentorial intracerebral hemorrhage: a randomized double-blind, placebo-controlled trial in postoperativepatients

Methylprednisolone for primary supratentorial intracerebral hemorrhage: a randomized double-blind, placebo-controlled trial in postoperativepatients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10001162
Enrollment
Unknown
Registered
2010-12-26
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperation acute primary supratentorial intracerebral hemorrhage

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age from 18 to 80 years; 2. Acute spontaneous supratentorial ICH; 3. underwent of hematoma evacuation; 4. Admission within 24 hours of ictus

Exclusion criteria

Exclusion criteria: 1. The haemorrhage was probably due to an aneurysm or an angiographically proven intracranial vascular malformation; 2. Associated with head injury or traumatic history; 3. Patients had severe pre-existing physical and/or mental disability; 4. Associated with infratentorial ICH; 5. Coagulation disorders or history of anticoagulant; 6. History of gastric ulcer or diabetes mellitus; 7. Hypoimmunity or infection; 8. Patients received any drugs which may influnce blood sugar, immunity, gastrointestinal function or the methylprednisolone metabolism 1month prior to the enrollment; 9. Hepatic and/or renal dysfunction.

Design outcomes

Primary

MeasureTime frame
Infection, gastrointestinal bleeding, hyperglycemia, fever, electrolyte disturbances;

Secondary

MeasureTime frame
Mortality, GCS score, GOS score, Modified Rankin Scale;Change of vital signs;

Countries

China

Contacts

Public ContactChao You
mdzhoubo@gmail.com+86 18628119825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026